Connect with us


ProMIS appointment to drive biotech development

Avatar photo



Biotech firm ProMIS Neurosciences has appointed Dr. Cheryl Wellington to its scientific advisory board.

ProMIS is focused on the discovery and development of antibody therapeutics, targeting misfolded proteins such as toxic oligomers implicated in the development of neurodegenerative diseases.

Dr. Cheryl Wellington is professor of pathology and laboratory medicine at the University of British Columbia (UBC), has built an internationally recognized research programme that focuses on neurological diseases, with a particular emphasis on Alzheimer’s Disease (AD) and traumatic brain injury (TBI).  

“We are delighted to welcome Dr. Wellington to the ProMIS SAB,” stated Dr. Neil Cashman, ProMIS’ chief scientific officer.

“In addition to her outstanding contributions to the understanding of AD and TBI, we are duly impressed by her research group that is one of the most experienced in North America on ultrasensitive blood-based biomarker tests for a number of neurological and neurodegenerative conditions, including Alzheimer’s disease.”

The emerging ability to measure biomarkers such as NfL (neurofilament light chain), P-tau (phosphorylated tau protein) and GFAP (glial fibrillary acidic protein) in blood samples as opposed to cerebrospinal fluid (CSF) offers several advantages such as its relatively non-invasive nature, lower risk of complications and ease with which blood draws can be repeated on a regular basis.

These advantages make blood-based biomarkers ideal tools in AD clinical trials to assist in diagnosis and monitoring of patient progress on therapy.

Dr. Wellington stated: “ProMIS’s approach to targeting the root cause of many brain diseases is of exceptional interest and importance. I am honored to join the Scientific Advisory Board to advise and assist in their programmes.”

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending stories